$0.00
USD 0.00(0.00%)
1 month
Volume
Market Cap
52 Week
Prev. Close
About SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Sector
Health Technology
CEO
Marco Taglietti
Industry
Pharmaceutical
Exchange
NAS
Website
Top Stories
Coming soon.